Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
Kashif M Munir,1 Stephen N Davis2 1Division of Endocrinology, Diabetes, and Nutrition, Center for Diabetes and Endocrinology, 2Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA Abstract: With rates of obesity and diabetes rising across the world, effective therap...
Main Authors: | Munir KM, Davis SN |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-04-01
|
Series: | Clinical Pharmacology : Advances and Applications |
Subjects: | |
Online Access: | https://www.dovepress.com/differential-pharmacology-and-clinical-utility-of-empagliflozin-in-typ-peer-reviewed-article-CPAA |
Similar Items
-
Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
by: Andrew Ahmann
Published: (2015-11-01) -
Liver Transcriptomic Reveals Novel Pathways of Empagliflozin Associated With Type 2 Diabetic Rats
by: Qiuyue Lv, et al.
Published: (2020-03-01) -
Empagliflozin in type 1 diabetes
by: Mathieu C, et al.
Published: (2019-08-01) -
A NEW INDICATION FOR EMPAGLIFLOZIN: TURNING POINT IN THE TREATMENT OF TYPE 2 DIABETES
by: M. V. Amosova, et al.
Published: (2017-12-01) -
Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
by: Antonio Ceriello, et al.
Published: (2020-10-01)